Company intelligence / Profile preview

Shauds

San Francisco, California, United Statesnyc.gov ↗

Ownership: Private
Development stage: Other

Overview

Shasqi has demonstrated, for the first time in humans, that in vivo click chemistry can be used to pre-target and concentrate therapeutics at tumor sites. Their lead program SQ3370 enables delivery of up to 12-fold higher doses of doxorubicin per cycle compared to conventional approaches while reducing systemic toxicity. Preclinical and early clinical data support improved safety and efficacy profiles.

Therapeutic areas: Oncology
Modalities: Small moleculeProdrugChemotherapy (via click chemistry-enabled delivery)
Industry: Biotech

Beyond the preview

Go deeper on Shauds.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shauds.

Explore the full profile